Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.12 AUD | +4.25% | +4.71% | +15.77% |
Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
Feb. 25 | Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024 |
Sales 2024 * | 384M 248M | Sales 2025 * | 429M 277M | Capitalization | 554M 357M |
---|---|---|---|---|---|
Net income 2024 * | -83M -53.53M | Net income 2025 * | -2M -1.29M | EV / Sales 2024 * | 1.25 x |
Net cash position 2024 * | 72.1M 46.5M | Net cash position 2025 * | 60.91M 39.28M | EV / Sales 2025 * | 1.15 x |
P/E ratio 2024 * |
-6.67
x | P/E ratio 2025 * |
-199
x | Employees | 967 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.67% |
Latest transcript on Mayne Pharma Group Limited
1 day | +4.25% | ||
1 week | +4.71% | ||
Current month | -1.66% | ||
1 month | +4.25% | ||
3 months | +37.98% | ||
6 months | +95.60% | ||
Current year | +15.77% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Aaron Gray
DFI | Director of Finance/CFO | - | 22-08-28 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 18-05-29 |
Patrick Blake
BRD | Director/Board Member | 59 | 18-06-27 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 7.12 | +4.25% | 197 322 |
24-04-22 | 6.83 | +2.55% | 246,992 |
24-04-19 | 6.66 | -1.33% | 130,562 |
24-04-18 | 6.75 | +1.35% | 105,398 |
24-04-17 | 6.66 | -2.06% | 79,559 |
Delayed Quote Australian S.E., April 23, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.77% | 357M | |
+17.88% | 44.31B | |
+19.87% | 22.17B | |
+14.93% | 14.62B | |
+8.06% | 13.12B | |
+39.21% | 11.58B | |
-8.96% | 6.96B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+6.50% | 5.03B |
- Stock Market
- Equities
- MYX Stock